Glucagon-like peptide-1 (GLP-1), a gut hormone secreted from L cells in the intestine in
response to food intake, not only augments glucosedependent insulin secretion from …

Vildagliptin is a stable inhibitor of dipeptidyl peptidase-IV, a responsible enzyme that mainly
inactivates glucagon-like peptide-1, and now one of the widely used agents for the treatment …

Hyperglycemia or high blood sugar is one of the major pathological characteristics of
diabetes. The endothelium is the inner layer of the vascular wall and is directly exposed to …

Background/Aims: Vildagliptin is an oral inhibitor of dipeptidyl peptidase-4, an enzyme
mainly responsible for inactivating incretins, and one of the widely used drugs for the …

Dipeptidyl peptidase-4 (DPP-4) inhibitors are novel anti-hyperglycemic drugs for type 2
diabetes. It has been reported that DDP-4 inhibitor could exert pleiotropic effects on …

Background Heart failure with left ventricular (LV) hypertrophy is often associated with
insulin resistance and inflammation. Recent studies have shown that dipeptidyl peptidase 4 …

BACKGROUND AND AIMS: It is believed that oxidative stress plays a role in the
pathogenesis of diabetes mellitus. Several strategies have been developed with the …

Vildagliptin is a representative of Dipeptidyl Peptidase-4 (DPP-4) inhibitors,
antihyperglycemic drugs, approved for use as monotherapy and combination therapy in type …

Background Progressive remodeling after myocardial infarction (MI) is a leading cause of
morbidity and mortality. Recently, glucagon-like peptide (GLP)-1 was shown to have …

Glucagon-like peptide-1 (GLP-1) is one of the incretins, a gut hormone secreted from L-cells
in the intestine in response to food intake [1, 2]. Since GLP-1 augments glucose-induced …